AlloSite Tx
  • Home
  • About Us
    • Our Mission
    • Our Team
  • Science
    • Pipeline
    • Publications
    • Our White Papers
  • Platform
  • News
  • Careers
  • Investors
Select Page

Allosite Therapeutics to use generic name Ontegimod for its clinical lead

by Santiago Balza Pineda | Aug 9, 2023 | Announcement

Miami, Florida, August 9th, 2023 — Allosite Therapeutics (DBA of 149 Bio, LLC) has announced its generic name for its clinical stage, lead candidate as Ontegimod (pronounced aun-teh-gi-mod). The company recently obtained rights to this molecule as part of its...

Recent Posts

  • Allosite Therapeutics to use generic name Ontegimod for its clinical lead
  • AlloSite Therapeutics launches
  • Acquisition of clinical stage integrin activator program from Gossamer Bio
  • Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease

Recent Comments

    Archives

    • August 2023
    • February 2023
    • October 2022

    Categories

    • Announcement
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org